Alicia Barreiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alicia Barreiro has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Carrera
Melanoma Unit, Dermatology Department, Hospital Clínic De Barcelona, IDIBAPS, Universitat De Barcelona, Barcelona, Spain
11 shared publications - Susana Puig
Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain
11 shared publications - Josep Malvehy
Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain
8 shared publications - Sebastian Podlipnik
Melanoma Unit, Dermatology Department, Hospital Clínic De Barcelona, IDIBAPS, Universitat De Barcelona, Barcelona, Spain
6 shared publications Josep Malvehy
Dermatology Department Hospital Clínic & Melanoma Group IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer) Barcelona Spain
4 shared publications- Miriam Potrony
Center for Biomedical Network Research on Rare Diseases (CIBERER) Carlos III Health Institute Barcelona Spain
4 shared publications
Latest Publications
- 29 May 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (10) , E688-E690
Sutton’s naevi as a pitfall for reflectance confocal microscopy: marked inflamed naevi could not be suitable for teleconfocal examination
Reflectance confocal microscopy (RCM) has been widely demonstrated to improve the noninvasive diagnostic accuracy of melanocytic tumors1. Some studies have focused on studying the use of teleconsultation of RCM images with experts as a promising opportunity for those doctors who have little experience in the field2. The clinical diagnosis of Sutton’s naevus is usually straightforward3: a melanocytic naevus surrounded by a symmetrical white circle4; however, sometimes inflammation makes identifying this entity challenging, as it can present atypical clinical and dermoscopic features. This atypical presentation of Sutton’s naevi can pose a diagnostic challenge. In addition, some groups, including ours, have recently published the confocal findings of such equivocal Sutton’s naevi5,6.
- 29 May 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (10) , E688-E690
Sutton’s naevi as a pitfall for reflectance confocal microscopy: marked inflamed naevi could not be suitable for teleconfocal examination
Reflectance confocal microscopy (RCM) has been widely demonstrated to improve the noninvasive diagnostic accuracy of melanocytic tumors1. Some studies have focused on studying the use of teleconsultation of RCM images with experts as a promising opportunity for those doctors who have little experience in the field2. The clinical diagnosis of Sutton’s naevus is usually straightforward3: a melanocytic naevus surrounded by a symmetrical white circle4; however, sometimes inflammation makes identifying this entity challenging, as it can present atypical clinical and dermoscopic features. This atypical presentation of Sutton’s naevi can pose a diagnostic challenge. In addition, some groups, including ours, have recently published the confocal findings of such equivocal Sutton’s naevi5,6.
- 23 April 2020
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 33 (5) , 685-694
Melanocortin‐1 receptor (MC1R) genotypes do not correlate with size in two cohorts of medium‐to‐giant congenital melanocytic nevi
Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in MC1R, such as p.V92M and loss‐of‐function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in two distinct cohorts of medium‐to‐giant CMN patients from Spain (N = 113) and from France, Norway, Canada, and the United States (N = 53), similar at the clinical and phenotypical level except for the number of nevi per patient. We found that the p.V92M or loss‐of‐function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case–control analysis with 259 unaffected Spanish individuals showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; p = .075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non‐UK cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development.
- 23 April 2020
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 33 (5) , 685-694
Melanocortin‐1 receptor (MC1R) genotypes do not correlate with size in two cohorts of medium‐to‐giant congenital melanocytic nevi
Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in MC1R, such as p.V92M and loss‐of‐function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in two distinct cohorts of medium‐to‐giant CMN patients from Spain (N = 113) and from France, Norway, Canada, and the United States (N = 53), similar at the clinical and phenotypical level except for the number of nevi per patient. We found that the p.V92M or loss‐of‐function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case–control analysis with 259 unaffected Spanish individuals showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; p = .075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non‐UK cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development.
- Open Access
Melanocortin-1 receptor ( MC1R ) genotypes do not correlate with size in two cohorts of medium-to-giant congenital melanocytic nevi
Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in the MC1R gene, such as p.V92M and loss-of-function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in 113 medium-to-giant CMN patients from Spain and from a distinct cohort of 53 patients from France, Norway, Canada and the U.S. These cohorts were similar at the clinical and phenotypical level, except for the number of nevi per patient. We found that the p.V92M or loss-of-function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case-control analysis with 259 unaffected Spanish individuals, showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; P =0.075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non-U.K. cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development. SIGNIFICANCE: Congenital melanocytic nevi (CMN) are common pigmented lesions that originate during prenatal life, without clear evidence of a genetic predisposition. To date, limited data exist regarding the role of the MC1R gene, a key regulator of human pigmentation, in the development of the class of rarer CMN that are greater than 10 cm diameter at projected adult size and associated with increased morbidity or mortality risks. This study provides data from a large set of such CMN patients to support the hypothesis that MC1R could be involved in the development of these types of lesions, but at the same time discounting its influence on the size of CMN across distinct populations. Improving our understanding of genetic susceptibility to rare types of CMN is necessary to determine whether routine germline genotyping is relevant in clinical practice.
Open AccessMelanocortin-1 receptor ( MC1R ) genotypes do not correlate with size in two cohorts of medium-to-giant congenital melanocytic nevi
Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., genetic variants in the MC1R gene, such as p.V92M and loss-of-function variants, have been previously associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics in 113 medium-to-giant CMN patients from Spain and from a distinct cohort of 53 patients from France, Norway, Canada and the U.S. These cohorts were similar at the clinical and phenotypical level, except for the number of nevi per patient. We found that the p.V92M or loss-of-function MC1R variants either alone or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional case-control analysis with 259 unaffected Spanish individuals, showed a higher frequency of MC1R compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the control population (15.9% vs. 9.3%; P =0.075). Altogether, this study suggests that MC1R variants are not associated with CMN size in these non-U.K. cohorts. Additional studies are required to define the potential role of MC1R as a risk factor in CMN development. SIGNIFICANCE: Congenital melanocytic nevi (CMN) are common pigmented lesions that originate during prenatal life, without clear evidence of a genetic predisposition. To date, limited data exist regarding the role of the MC1R gene, a key regulator of human pigmentation, in the development of the class of rarer CMN that are greater than 10 cm diameter at projected adult size and associated with increased morbidity or mortality risks. This study provides data from a large set of such CMN patients to support the hypothesis that MC1R could be involved in the development of these types of lesions, but at the same time discounting its influence on the size of CMN across distinct populations. Improving our understanding of genetic susceptibility to rare types of CMN is necessary to determine whether routine germline genotyping is relevant in clinical practice.
- 1 February 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (2) , 263-271
Factors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanoma
- 1 February 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (2) , 263-271
Factors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanoma
- 1 December 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (6) , 1330-1338
Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study
- 1 December 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (6) , 1330-1338
Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study
- Open Access
- 1 July 2019
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 99 (9) , 777-782
Clinical and Dermoscopic Evaluation of Melanocytic Lesions in Patients with Chronic Graft Versus Host Disease
Patients treated with haematopoietic stem cell transplantation are at increased risk of cutaneous ma...
- 1 July 2019
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 99 (9) , 777-782
Open AccessClinical and Dermoscopic Evaluation of Melanocytic Lesions in Patients with Chronic Graft Versus Host Disease
Patients treated with haematopoietic stem cell transplantation are at increased risk of cutaneous ma...
- 13 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 83 (4) , 1057-1063
Improvement of diagnostic confidence and management of equivocal skin lesions by integration of reflectance confocal microscopy in daily practice: Prospective study in 2 referral skin cancer centers
- 13 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 83 (4) , 1057-1063
Improvement of diagnostic confidence and management of equivocal skin lesions by integration of reflectance confocal microscopy in daily practice: Prospective study in 2 referral skin cancer centers
- 18 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 382-389
Detection of cell‐free circulating BRAF V 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance
Background The p.V600E mutation in the BRAF gene (BRAFV600E) is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. The analysis of cell‐free BRAFV600E mutation (cfBRAFV600E) in plasma has emerged as a biomarker for monitoring prognosis and treatment response in melanoma patients. Objectives To quantify cfBRAFV600E levels in plasma from melanoma patients and from patients without melanoma having regular follow‐up of their melanocytic lesions, in order to assess the clinical significance of the test. Methods We quantified cfBRAFV600E by droplet digital PCR in plasma from 146 patients without melanoma undergoing continuous dermatological screening, 26 stage III and 7 stage IV patients with BRAF‐mutant melanoma, and 32 melanoma patients free of disease for 3 or more years. Results Among disease‐free patients and non‐melanoma individuals, 52% presented a high naevus count (>50) and 49% had clinically atypical naevi. cfBRAFV600E was detected in 71·4% of stage IV and 15·4% of stage III melanoma patients and in 1·4% of non‐melanoma individuals. No cfBRAFV600E was detected in disease‐free melanoma patients. Non‐melanoma individuals had lower cfBRAFV600E levels compared to melanoma patients. We established a variant allelic frequency of 0·26% or five cfBRAFV600E copies/mL as the optimal cut‐off value for identifying melanoma patients with >99% of specificity. Conclusions The study suggests that naevus related factors do not influence the detection of cfBRAFV600E in non‐melanoma individuals, and support the clinical diagnostic value of plasma cfBRAFV600E quantification in melanoma patients.
- 18 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 382-389
Detection of cell‐free circulating BRAF V 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance
Background The p.V600E mutation in the BRAF gene (BRAFV600E) is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. The analysis of cell‐free BRAFV600E mutation (cfBRAFV600E) in plasma has emerged as a biomarker for monitoring prognosis and treatment response in melanoma patients. Objectives To quantify cfBRAFV600E levels in plasma from melanoma patients and from patients without melanoma having regular follow‐up of their melanocytic lesions, in order to assess the clinical significance of the test. Methods We quantified cfBRAFV600E by droplet digital PCR in plasma from 146 patients without melanoma undergoing continuous dermatological screening, 26 stage III and 7 stage IV patients with BRAF‐mutant melanoma, and 32 melanoma patients free of disease for 3 or more years. Results Among disease‐free patients and non‐melanoma individuals, 52% presented a high naevus count (>50) and 49% had clinically atypical naevi. cfBRAFV600E was detected in 71·4% of stage IV and 15·4% of stage III melanoma patients and in 1·4% of non‐melanoma individuals. No cfBRAFV600E was detected in disease‐free melanoma patients. Non‐melanoma individuals had lower cfBRAFV600E levels compared to melanoma patients. We established a variant allelic frequency of 0·26% or five cfBRAFV600E copies/mL as the optimal cut‐off value for identifying melanoma patients with >99% of specificity. Conclusions The study suggests that naevus related factors do not influence the detection of cfBRAFV600E in non‐melanoma individuals, and support the clinical diagnostic value of plasma cfBRAFV600E quantification in melanoma patients.
- Open Access
- 23 April 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (1) , 138-146
Inherited MC 1R variants in patients with melanoma are associated with better survival in women
Background Females have a better melanoma prognosis and fairer skin and hair colour. The presence of inherited MC1R variants has been associated with a better melanoma prognosis, but its interaction with sex is unknown. Objectives To evaluate the relationship between germline MC1R status and survival and determine any association with gender. Methods Cohort study including 1,341 melanoma patients from the Melanoma Unit of the Hospital Clínic of Barcelona, between January 1996 and April 2018. We examined known sex‐related prognosis factors as they relate to melanoma features and evaluated the sex‐specific role of the MC1R gene in overall survival and melanoma‐specific survival. Hazard ratios (HR) were calculated using univariate and multivariate Cox logistic regression. Results Males showed lower overall survival than females (P<.001) and the presence of inherited MC1R variants was not associated with better survival in our cohort. However, in the subgroup of female patients the presence of MC1R variants was associated with better overall survival in the multivariate analysis (HR 0.57; 95% CI 0.38‐0.85; P=.006), but not in male patients (HR 1.26; 95% CI 0.89‐1.79; P=.185) (P‐value for interaction P=.004). Analysis performed for melanoma‐specific survival showed the same level of significance. Limitations This was a single‐centre retrospective study. Conclusions Inherited MC1R variants is associated with improved overall survival in women with melanoma but not in men. Intrinsic sex‐dependent features can modify the role of specific genes in melanoma prognosis. We believe, therefore, that survival studies of melanoma patients should include analysis by sex and MC1R genotype.
- 23 April 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (1) , 138-146
Open AccessInherited MC 1R variants in patients with melanoma are associated with better survival in women
Background Females have a better melanoma prognosis and fairer skin and hair colour. The presence of inherited MC1R variants has been associated with a better melanoma prognosis, but its interaction with sex is unknown. Objectives To evaluate the relationship between germline MC1R status and survival and determine any association with gender. Methods Cohort study including 1,341 melanoma patients from the Melanoma Unit of the Hospital Clínic of Barcelona, between January 1996 and April 2018. We examined known sex‐related prognosis factors as they relate to melanoma features and evaluated the sex‐specific role of the MC1R gene in overall survival and melanoma‐specific survival. Hazard ratios (HR) were calculated using univariate and multivariate Cox logistic regression. Results Males showed lower overall survival than females (P<.001) and the presence of inherited MC1R variants was not associated with better survival in our cohort. However, in the subgroup of female patients the presence of MC1R variants was associated with better overall survival in the multivariate analysis (HR 0.57; 95% CI 0.38‐0.85; P=.006), but not in male patients (HR 1.26; 95% CI 0.89‐1.79; P=.185) (P‐value for interaction P=.004). Analysis performed for melanoma‐specific survival showed the same level of significance. Limitations This was a single‐centre retrospective study. Conclusions Inherited MC1R variants is associated with improved overall survival in women with melanoma but not in men. Intrinsic sex‐dependent features can modify the role of specific genes in melanoma prognosis. We believe, therefore, that survival studies of melanoma patients should include analysis by sex and MC1R genotype.